On 19 September 2019, the Social Security (Industrial Injuries) (Prescribed Disease) Amendment Regulations 2019 were tabled in Parliament. They came into force on 9 December 2019. With their passing, they brought into the spotlight a ‘new’ prescribed disease from the use of vibratory tools at work: Dupuytren’s Contracture. On the back of this, there will inevitably be new vibration-induced disease claims which will emerge in addition to the existing cohort of HAVS, VWF and vibration-induced CTS.
For those unfamiliar with the condition, Dupuytren’s Contracture is a deformity of the hand (and more specifically, the ring and little fingers) which is caused by the development of hardened fibrotic tissue in the palm of the hand which then causes the ring or little ringers (or sometimes both in extreme cases) to contract inwards and unable to be straightened. A typical example is shown in the image below:
The link between vibration exposure and the development of the condition is not clear-cut. It has been debated for some time and was put into considerable focus by the Industrial Injuries Advisory Council (“IIAC”) in 2006 when “some” link was thought to exist. It is notable that, even today, the NHS website does not refer to the use of hand-held tools (be they vibratory or not) as being a possible cause of the condition. Likewise, rarediseases.org also do not list vibration or occupational factors as being a potential cause of the condition.
However, in 2014, the IIAC commissioned a report which ultimately concluded that the use of vibratory tools at work ‘more than doubled’ the risk of the development of the condition and therefore recommended that Dupuytren’s Contracture become a prescribed disease for the purposes of Industrial Injuries Benefit:
“The [IIAC’s] inquiries in this area have included a detailed review of the research literature, consultation with experts in the field, and fresh analyses of three existing datasets held by other parties. When taken together, the evidence indicates that risks of the disease can be more than doubled (the threshold commonly employed in deciding on prescription under the IIDB Scheme), provided that exposures to vibration are sufficiently long.”
In pinning down the exposure qualification criteria for those with demonstratable Dupuytren’s Contracture, the report recommended as follows at paragraph 50:
“In considering a workable definition of the qualifying exposure(s), the Council feels that a duration of exposure at least ten years in aggregate (to the extent of two or more hours per day on three or more days per week) would be an appropriate cut-off point.”
In 2017, however, the Government turned down that recommendation. Subsequently, it transpired that a meeting was requested by the IIAC to discuss the issue further, at which the Government were persuaded to endorse the original recommendation, including the recommendation as to exposure criteria: see page 11 of the IIAC’s latest Annual Report (July 2019).
Against that background, regulation 2(3) of the Social Security (Industrial Injuries) (Prescribed Disease) Amendment Regulations 2019 now formally confirms that Dupuytren’s Contracture is a prescribed disease and the Social Security (Industrial Injuries) (Prescribed Disease) Regulations 1985 have been amended accordingly.
Does the Court have jurisdiction over compliance with the Pre-Action Protocol for Low Value RTA Claims (“the Protocol”)? In its decision of 24 June 2025, the Court of Appeal decided in MH Site Maintenance Services Limited and another v James Watson [2025] EWCA Civ 775 that, when proceedings have been issued, the answer is “yes.”…
In the recent Judgment of Edwards and ors v 2 Sisters Food Group Limited [2025] EWHC 1312 (KB), Sir Peter Lane considered causation in work-related COVID-19 claims and the courts’ approach to a summary judgment application where further evidence may yet be adduced by the respondent. This Judgment is of significance for anyone dealing with…
Philip Turton adds to his article on URS Corporation Limited v BDW Trading Limited. This article can be read here. Two weeks ago I wrote about the effect of URS Corporation Limited v BDW Trading Limited [2025] UKSC 21 (“URS Corporation”) on claims for contribution in mesothelioma cases. The effect of the decision in the…